1. Medtech Insight
  2. >>Policy & Regulation

Companies Support Telehealth Reforms – But Seek Demo Projects First

Responding to a chronic care reform effort by the Senate Finance Committee, AdvaMed, device firms and several medical groups asked for demo projects and waivers to appropriately expand the use of telehealth services.

Device firms are pleased that the Senate Finance Committee is exploring options to increase access to telehealth services for patients with chronic conditions, but they want to ensure that reimbursement models are tested on a small scale before wider roll out, AdvaMed and other industry groups told the committee.

The Finance Committee released its “Bipartisan Chronic Care Working Group Policy Options”

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legislation

More from Policy & Regulation

Health Secretary Defends Spending Cuts During Senate Hearing On HHS Budget

 
• By Elizabeth Orr

Health and Human Services Secretary Robert F. Kennedy Jr. emphasized administrative cost reductions and defended budget decisions during a Senate hearing on HHS funding. Some senators, however, expressed concerns over the impacts spending cuts had on essential health programs.

Tariffs Threaten Medtech Innovation And US Position As World Leader, Whitaker Tells Lawmakers

 
• By Brian Bossetta

During his testimony before US senators on the impact of tariffs on critical supply chains, AdvaMed’s Scott Whitaker said the Trump tariffs could jeopardize America’s preeminence in medtech. Other industry experts echoed similar concerns.

Califf Warns Progress May Be In Danger Due To ‘Decimated’ FDA Staff

 
• By Barnaby Pickering

In Vivo spoke to the previous commissioner of the US FDA about recent ongoings at the agency, and where he believes policy should be directed for patient and industry benefit.